retatrutide trials safety VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide—A Game Changer in Obesity

Escalating Use of GLP-1RAs in Obesity Management GLP-1 agonists, such as semaglutide, received significant attention in 2023 [56]

The starting dose for insulin-naive type 2 diabetes patients is typically 10 units once daily

Fats pack calories, so portion them tightly

Hashimoto's disease itself is not a contraindication to GLP-1 receptor agonist use

Full Article Link: #Biomall #CKD #Lubiprostone #Nephrology #KidneyResearch #GutKidneyAxis #ChronicKidneyDisease #MedicalResearch #TohokuUniversity #HealthNews #TranslationalMedicine To view or add a comment, sign in The Golden Era of Incretin Therapy: A Visual Summary As a General Practitioner, keeping pace with the rapid evolution of GLP-1 Receptor Agonists (and the new twincretins) is both a challenge and a privilege